Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder for prior CAR-T therapies to detect and fight.
"This next-generation approach, called ALA-CART (adjunctive LAT-activating CAR-T cells), optimizes CAR-T cells to more effectively eliminate cancer cells, including those that have been able to hide from traditional CAR-T cells," said Catherine Danis, PhD, lead author and postdoctoral fellow at the University of Colorado School of Medicine.
CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body. But some cancer cells can evade detection by CAR-T cells, leading to treatment failure and relapse. Using human T cells and leukemia cells in specialized mouse models, researchers developed the novel ALA-CART cells which showed promising results in fighting acute lymphocytic leukemias that were resistant to traditional CAR-T cells.
Know more: https://www.sciencedaily.com/releases/2025/03/2503...

• Tags:
• News